Navigate Fool.com
Will BIIB beat
the market?

Biogen Idec


Community Rating: 4 Stars: Favorite

285.49 5.97 (2.14%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $280.55
Previous Close $279.52
Daily Range $272.02 - $288.84
52-Week Range $194.66 - $358.89
Market Cap $67.5B
P/E Ratio 35.08
Dividend (Yield) $0.00 (0.0%)
Volume 1,871,285
Average Daily Volume 2,033,057
Current FY EPS $11.29

How do you think BIIB
will perform against the market?

Top BIIB Bull/Bear Pitches


StockDocStan (1.9)
Submitted September 7, 2011

The clear leader in the independent biotechs is NOT likely to stay independent for long. I expect a buyout by Roche or even Pfizer or Merck in the next 6 months.

0 Replies Reply Report this Post

NetscribeBiotech (< 20)
Submitted February 19, 2007

Biogen Idec Inc, born in 2003 post the merger of Biogen and Idec Pharmaceuticals, develops, manufactures and commercializes novel therapies. With five approved products viz. Avonex, Rituxan, Tysabr, A … More

4 Replies Reply Report this Post

News & Commentary Rss Feed

Health Care Stocks: Check Out This Low-Cost Market Beater

These health care stocks have been growing by double digits. Should you buy?

Biotech Bubble Bust: 2 Ways to Win

Why Gilead and Biogen are the best ways to play the biotech meltdown.

Are Biotechs Bad Medicine for the S&P 500?

Are biotechs to blame for the recent downturn in the S&P 500?

Why Biogen Idec Inc., Vertex Pharmaceuticals Incorporated, and Broadcom Corp. Are Today’s 3 Worst St

Health-care and high-growth names continue to stumble as a sell-off continues in the stock market today.

Tech stock rout continues in Asia

Asia tech stocks fall into the red

Stocks: Wall Street wears red

Why Gilead Sciences, AbbVie Inc., and Biogen Idec Are Today's 3 Worst Stocks

The 3 worst stocks in the stock market today all hail from the health care sector

Tweet of the Week: Big Biotech Dominates Industry Gains

Amgen, Biogen Idec, Celgene, Gilead Sciences, Regeneron Pharmaceuticals, and Alexion Pharmaceuticals make up 77% of the increase in the biotech sector over the past three years.

Does Biogen Idec Inc Have a New Blockbuster Hemophilia Therapy?

Biogen's Alprolix is now the most convenient hemophilia B treatment available, but competition is on the way.

Credit Suisse Says Grit Your Teeth and Buy Biotech

See More BIIB News...





Biogen Idec (BIIB) Description

The Company creates new standards of care in oncology, neurology, immunology and other specialty areas of unmet medical need and engaged in the development, manufacturing, and commercialization of novel therapies. Website: http://www.biogenidec.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks